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Running head: Switching NRTI in second-line ART 
 
 
Abstract 
Background 
After first-line antiretroviral therapy (ART) failure, the importance of change in nucleoside 
reverse transcriptase inhibitor (NRTI) in second-line is uncertain due to the high potency of 
protease inhibitors used in second-line.  
 
Setting 
We used clinical data from 6,290 adult patients in South Africa and Zambia from the 
International Epidemiologic Databases to Evaluate AIDS-Southern Africa cohort.  
 
Methods 
We included patients who initiated on standard first-line ART and had evidence of first-line 
failure. We used propensity score-adjusted Cox proportional hazards models to evaluate the 
impact of change in NRTI on second-line failure compared to remaining on the same NRTI in 
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second-line. In South Africa, where viral load monitoring was available, treatment failure was 
defined as two consecutive viral loads >1,000 copies/mL. In Zambia, it was defined as two 
consecutive CD4 counts <100 cells/mm3. 
 
Results 
Among patients in South Africa initiated on zidovudine, the adjusted hazard ratio for second-line 
virologic failure was 0.25 (95% CI: 0.11, 0.57) for those switching to tenofovir vs. remaining on 
zidovudine. Among patients in South Africa initiated on tenofovir, switching to zidovudine in 
second-line was associated with reduced second-line failure (adjusted hazard ratio = 0.35 [95% 
CI: 0.13, 0.96]). In Zambia where viral load monitoring was not available, results were less 
conclusive. 
 
Conclusion 
Changing NRTI in second-line was associated with better clinical outcomes in South Africa. 
Additional clinical trial research regarding second-line NRTI choices for patients initiated on 
tenofovir or with contraindications to specific NRTIs is needed. 
 
Keywords 
Antiretroviral therapy; South Africa; Zambia; Second-line; nucleoside reverse transcriptase 
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Introduction 
Although drug resistance is rare at antiretroviral therapy (ART) initiation, most patients 
who fail first-line ART have some resistance to nucleoside reverse transcriptase inhibitors 
(NRTIs) that are also used in second-line regimens(1-6). In order to optimize the efficacy of 
NRTIs in second-line, national treatment guidelines in South Africa and Zambia recommend 
patients change at least one NRTI when switching to second-line(7-11). In practice, changing 
NRTIs does not always occur, usually due to contraindications to specific NRTIs or lack of 
availability. 
The importance of NRTI activity in second-line ART is questioned due to the high 
potency of standard protease inhibitors (PIs) in second-line, lopinavir/ritonavir. Second-line ART 
can successfully suppress HIV in the presence of NRTI drug resistance mutations(12-17), yet the 
number of NRTIs switched from first- to second-line ART is associated with improved outcomes 
on second-line(18). We investigated the impact of switching NRTIs on virologic and 
immunologic outcomes as patients in South Africa and Zambia reach multiple years on second-
line.  
 
Methods 
We used data from the International Epidemiologic Databases to Evaluate AIDS 
Southern Africa (IeDEA-SA) cohort, a National Institutes of Health funded initiative pooling 
data to address HIV treatment research questions. IeDEA-SA data included medical records from 
2004-2013 from 175,933 patients in Zambia and 79,908 patients South Africa, with information 
on basic patient demographics, height, weight, date of visits, diagnoses, ART drugs, and lab 
values, including CD4 and, in South African sites, HIV viral load.  
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The study population included adult patients ≥18 years, initiated on standard first-line 
ART (2 NRTIs plus a non-nucleoside reverse transcriptase inhibitor (NNRTI)), and had evidence 
of first-line failure: either a viral load >1,000 copies/mL among South African patients after at 
least six months on treatment, or 2 consecutive CD4 counts <100 or a 30% drop from highest 
CD4 count among Zambian patients. The first NRTI used in first- and second-line was 
categorized into zidovudine (AZT), stavudine (d4T), tenofovir (TDF), abacavir (ABC), or other. 
We evaluated switch to each type of NRTI for patients: (1) initiated on zidovudine, (2) initiated 
on stavudine, and (3) initiated on tenofovir. 
Treatment failure on second-line was our primary outcome and was modeled with crude 
and propensity score-adjusted Cox proportional hazards regression where propensity score was 
included in the models as a covariate. Our primary analysis used data from South Africa, where 
viral load monitoring was available, and treatment failure was defined as two consecutive viral 
loads >1,000 copies/mL. We also evaluated immunologic failure on second-line ART in Zambia, 
where treatment failure was persistent CD4 levels below 100 cells/mm3, defined as two 
consecutive CD4 counts <100 cells/mm3(19,20). Potential confounders included year of starting 
second-line, age, sex, duration on first-line, and first-line NNRTI, as well as CD4 count, viral 
load, hemoglobin, and creatinine clearance at first-line initiation and at switch to second-line. 
Multiple imputation was used for missing covariates unless they were missing for >50% of 
patients(21,22). Propensity scores for switching to each type of NRTI versus remaining on the 
same NRTI were calculated for each model with logistic regression, which allowed us to control 
for as many confounders as possible while maximizing statistical efficiency(23).  
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For South Africa models, propensity scores were adjusted for year of switch to second-
line, gender, age, baseline alanine aminotransferase (ALT), hemoglobin, CD4, creatinine 
clearance, weight, and viral load and CD4 count at time of switch to second-line. Models for 
changing from tenofovir were not adjusted for year since it was only available in more recent 
years. For Zambia models, propensity scores were adjusted for year of switch to second-line, 
gender, age, baseline ALT, CD4, hemoglobin, weight, creatinine clearance, and second-line 
values of CD4, creatinine clearance, and hemoglobin. Models for changing from stavudine were 
not adjusted for year because the number initiated on stavudine who remained on stavudine in 
second-line was too small and propensity score models did not converge when year was 
adjusted. In sensitivity analyses, we adjusted for loss to follow-up through inverse probability of 
treatment weighting (24). 
 
Results 
Study sample  
 In South Africa, 4,614 patients had evidence of first-line virologic failure and switched to 
a PI-based regimen and in Zambia, 2,061 patients experienced first-line immunologic failure and 
switched to a PI-based regimen. Patients without visits after date of switch to second-line (2.5%) 
and patients who did not have any NRTI identified in the regimen at time of second-line 
initiation (3.2%) were excluded. The total sample included 6,290 patients (4,275 in South Africa 
and 2,015 in Zambia).  
 Among the 6,290 patients in analysis, the majority were female (61%) and the median 
age was 34 years (IQR: 29, 40).  A description of the patients is shown by country and by change 
in NRTI in second-line in Supplemental Digital Content Table 1.  
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In both countries, CD4 counts at ART initiation were low (median <100 cells/mm3), and CD4 
count at switch to second-line was slightly lower for patients who had a change in second-line 
NRTI in South Africa, but not in Zambia (Supplemental Digital Content Table 1). Overall, 90% 
of patients changed NRTIs at second-line (Table 1). In South Africa, the proportion who changed 
NRTI in second-line was mostly constant over time (92.5% in 2004-2006, 96.3% in 2007-2008, 
94.5% in 2009-2010, and 95.5% in 2011-2013). In Zambia, the proportion changing NRTIs was 
lower than in South Africa, and changing NRTI was more common in earlier periods (85.1% in 
2004-2006, 91.8% in 2007-2008, 80.3% in 2009-2010, and 72.4% in 2011-2013). 
Follow-up time on second-line was 18 months (IQR: 14-28) for South African patients 
and 23 months (IQR: 15-33) for Zambian patients. Second-line virologic failure occurred among 
15% of patients in South Africa, and second-line immunologic failure occurred among 7% of 
patients in Zambia. Death was recorded for 4% in South Africa and 2% in Zambia. On average 
in South Africa, patients who did not switch NRTIs received slightly more viral load monitoring 
measurements on second-line (1.6 per year) compared to patients who did switch NRTIs (1.4 per 
year). Yet in recent years viral load monitoring was done less frequently, with a mean of >1 
measures per year prior to 2011, and a mean of 1.0 measures per year in 2011 and later.   
 
Second-line Outcomes 
 Propensity score-adjusted Cox proportional hazards models for virologic failure in South 
Africa are shown in Table 2 (summary of propensity scores displayed in Supplemental Digital 
Content Table 2). Among patients initiated on zidovudine, we observed an association between 
switching to tenofovir and reduced second-line failure compared to staying on zidovudine 
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(adjusted hazard ratio (aHR) 0.25 (95%CI: 0.11, 0.57). Switching from zidovudine to abacavir 
was not associated with reduced failure. Among  
patients initiated on first-line stavudine, there was weak evidence for reduced hazards of failure 
on second-line associated with switching to tenofovir vs. remaining on stavudine (aHR = 0.70 
(95% CI: 0.42, 1.16)). Switching from stavudine to zidovudine did not have an association with 
reduced hazards of second-line failure. For patients initiating tenofovir in first-line, follow-up 
time was more limited because the drug was introduced into South Africa’s national program 
later than stavudine and zidovudine.  Changing to zidovudine in second-line vs. remaining on 
tenofovir was associated with decreased second-line failure (aHR: 0.35; 95%CI: 0.13, 0.96). 
While loss to follow-up was common (34% of patients), weighting models using inverse 
probability weights to account for loss to follow-up did not impact the hazard ratio point 
estimates. 
 Using patient data from Zambia to evaluate second-line immunologic failure showed 
similar trends, but all hazard ratio estimates had wide confidence intervals (Supplemental Digital 
Content Table 3). 
 
Discussions 
Among patients in South Africa who failed first-line and switched to second-line ART, 
change in NRTI was associated with reduced virologic failure on second-line for changes to 
tenofovir and for change from tenofovir to zidovudine. Changes to other NRTIs had no 
association with second-line failure. In Zambia, where virologic monitoring was not available 
and treatment failure on second-line was more poorly defined and likely underestimated(25-28), 
we did not see strong evidence of a benefit from changing NRTIs in second-line.  
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It is possible that drug resistance to NRTIs had an effect on second-line failure, yet 
previous research has shown that protease inhibitor-based second-line ART can successfully 
suppress HIV in the presence of NRTI drug resistance mutations and that poor adherence is a 
more likely cause of second-line failure(12-17,29). Given the importance of adherence, it is 
possible patients on tenofovir in second-line often had better outcomes because the drug was 
better tolerated. Interestingly, remaining on tenofovir in second-line after initiating tenofovir in 
first-line was common in Zambia, perhaps because of physician preference for this drug. This 
trend may explain why there was less switching of NRTIs in Zambia in recent years as tenofovir 
became available. We did not see any strong evidence for reduction in second-line immunologic 
failure associated with switching away from tenofovir in Zambia. Since most patients now 
initiate tenofovir-based regimens as first-line ART, further exploration into switching to 
zidovudine, which was associated with better second-line outcomes, compared to remaining on 
tenofovir in South Africa, is warranted. 
Zidovudine is no longer the preferred NRTI for first-line in Zambia or South Africa, 
however it may still be used for patients with contraindications to tenofovir (e.g., renal failure). 
First-line zidovudine in South Africa would typically only have been prescribed over stavudine 
(under 2004 guidelines) when patients had pre-existing peripheral neuropathy or were at 
increased risk of hyperlactatemia. Since tenofovir became available in South Africa in 2010, 
patients normally are only initiated on zidovudine if they have renal failure. In Zambia, 
zidovudine was a more common option in first-line, and was part of national guidelines before 
2010, but has now also been replaced by tenofovir. Our results showed evidence that switching 
from zidovudine to tenofovir was associated with reduced second-line failure but the impact of 
switching from zidovudine to abacavir was not clear. For patients initiated on zidovudine-based 
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regimens because of renal failure, switching to tenofovir in second-line may not be an option if 
contraindications remain, and more detailed research into treatment choices for this population is 
important. 
One of the main obstacles in this study is the potential for confounding by indication, 
which is common in observational studies of drug prescriptions. While propensity scores were 
used to make groups as comparable as possible with respect to their clinical profile, due to 
limited data available in medical records, there is likely residual confounding. Patients who stay 
on the same NRTI because of complications that prevent them from taking certain second-line 
drugs may have worse outcomes due to these contraindications. Alternatively, patients who 
switch NRTIs may include more patients who truly failed first-line ART rather than switching 
regimens for other reasons, and who may have worse outcomes on second-line ART. 
Additionally, lack of virologic monitoring in Zambia made it difficult to accurately identify 
second-line treatment failure and draw more conclusive results from these data. Another 
potential problem is differential surveillance of patients who remain on the same NRTIs 
compared to those who switch. We did not see large differences in monitoring between these 
groups, but monitoring frequency did change over time, along with use of NRTIs in second-line 
regimens, with modifications to national treatment guidelines, so we controlled for calendar time 
where possible. Lastly, although we had a large initial sample size, stratification by NRTI used 
limited the numbers in the models, and with a relatively short follow-up time on second-line, led 
to some imprecise results.  
Our results support that the NRTI in second-line plays a role in second-line outcomes and 
provide limited evidence in support of current guidelines to change NRTI in second-line, 
although the impact of NRTI on second-line activity may act through drug resistance, drug side 
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effects, or better tolerance of drugs associated with improved adherence. This study supports the 
need for more research regarding NRTI choices for patients with renal failure who fail 
zidovudine first-line regimens, ideally with drug resistance data, and more follow-up of patients 
initiated on tenofovir who must switch to second-line. Observational patient cohorts in South 
Africa and Zambia are challenging settings for answering these complex questions comparing 
prescription of different drugs, and more information from clinical trials is necessary. 
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Table 1. NRTI in second-line regimen stratified by first-line NRTI and country. 
NRTI initiated in 
first-line ART 
NRTI at 
second-
line 
initiation 
South Africa Zambia 
(N, %) (N, %) 
Initiated on AZT AZT 74 12.5 42 5.2 
 
TDF 253 42.8 598 73.7 
 
ABC 185 31.3 154 19 
 
d4T 3 0.5 15 1.9 
 
other 76 12.9 2 0.3 
  TOTAL 591   811   
Initiated on d4T d4T 294 9.4 37 4.5 
 
TDF 1088 34.8 572 69.2 
 
ABC 64 2.1 110 13.3 
 
AZT 1677 53.7 108 13.1 
 
other 0 0 0 0 
 
TOTAL 3123   827 
 
Initiated on TDF TDF 32 5.7 124 32.9 
 
AZT 474 84.5 138 36.6 
 
ABC 15 2.7 81 21.5 
 
d4T 38 6.8 34 9 
 
other 2 0.4 0 0 
  TOTAL 561   377   
AZT = zidovudine; TDF = tenofovir; ABC = abacavir; d4T = stavudine  
 
  
AC
CE
PT
ED
Copyright  2017 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
  
Table 2. Hazard ratios and 95% confidence intervals of second-line virologic failure among South African 
patients, using Cox proportional hazards models adjusted for propensity scores. 
 
Second-line NRTI 
First-line NRTI AZT d4T TDF ABC 
AZT (ref) 
 (x) 
 0.25 (0.11, 0.57) 1.08 (0.49, 2.37) 
d4T 1.19 (0.85, 1.68) (ref) 0.70 (0.42, 1.16) 
 (x)
 
TDF 0.35 (0.13, 0.96) 
 (x)
 (ref) 
 (x)
 
AZT = zidovudine; d4T = stavudine; TDF = tenofovir; ABC = abacavir 
ref = Reference category, compared to other estimates in the row 
x = Sample size too small  
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